Search results for "Disease onset"

showing 4 items of 4 documents

How repair-or-dispose decisions under stress can initiate disease progression

2020

Summary Glia, the helper cells of the brain, are essential in maintaining neural resilience across time and varying challenges: By reacting to changes in neuronal health glia carefully balance repair or disposal of injured neurons. Malfunction of these interactions is implicated in many neurodegenerative diseases. We present a reductionist model that mimics repair-or-dispose decisions to generate a hypothesis for the cause of disease onset. The model assumes four tissue states: healthy and challenged tissue, primed tissue at risk of acute damage propagation, and chronic neurodegeneration. We discuss analogies to progression stages observed in the most common neurodegenerative conditions and…

0301 basic medicineCell signalingDisease onsetBioinformaticsSystems biology02 engineering and technologyArticle03 medical and health sciencesMathematical BiosciencesTissue damageMedicineddc:610Systems NeuroscienceResilience (network)lcsh:ScienceSystems neuroscienceMultidisciplinarybusiness.industrySystems BiologyNeurodegenerationDisease progression021001 nanoscience & nanotechnologymedicine.diseaseCrosstalk (biology)030104 developmental biologylcsh:Q0210 nano-technologybusinessNeuroscienceNeuroscience
researchProduct

Interventions to Slow Aging in Humans: Are We Ready?

2015

The workshop entitled 'Interventions to Slow Aging in Humans: Are We Ready?' was held in Erice, Italy, on October 8-13, 2013, to bring together leading experts in the biology and genetics of aging and obtain a consensus related to the discovery and development of safe interventions to slow aging and increase healthy lifespan in humans. There was consensus that there is sufficient evidence that aging interventions will delay and prevent disease onset for many chronic conditions of adult and old age. Essential pathways have been identified, and behavioral, dietary, and pharmacologic approaches have emerged. Although many gene targets and drugs were discussed and there was not complete consens…

GerontologyAgingDisease onsetPrescription DrugsLongevityPsychological interventionReviewsBiologyAMP-Activated Protein KinasesGrowth hormoneAging; Anti-aging; Centenarians; Dietary restriction; Lifespan studies; Longevity gene; Longevity regulation; Cell Biology; AgingDietary interventionsBiological FactorsMicelongevity geneSettore BIO/13 - Biologia ApplicataAnimalsHumansSirtuinsProtein restrictionCentenarianInsulin-Like Growth Factor ILifespan studieCaloric RestrictionSettore MED/04 - Patologia GeneraleGeroscienceGene targetsRibosomal Protein S6 KinasesTOR Serine-Threonine Kinasesanti-agingdietary restrictionCell Biologydietary restriction ; lifespan studies ; longevity gene ; centenarians ; anti-aging ; longevity regulation ; aginglongevity regulation3. Good healthDietEnzyme ActivationGene Expression RegulationGrowth HormoneGenetics of agingcentenariansaging; anti-aging; centenarians; dietary restriction; lifespan studies; longevity gene; longevity regulationSignal Transductionlifespan studies
researchProduct

Mucopolysaccharidosis Type VII (Sly disease) survivors

2013

treatment. Onset of neurological symptoms at age 8 and in adolescence. Pair 4: L.M. died at age 5 months due to liver failure. P.M. (7 years): earlyinfantile form, despite treatment start at age 2 progressive neurological deterioration. Pair 5: R.K.: late-infantile form, untreated, died at age 9 due to progressive neurological involvement. M.K.: late infantileform, start of treatment at age 5, died at age 13 due to epileptic encephalopathy. These cases reveal that disease onset and progression in siblings with NPC vary, and that miglustat can slow disease progression.

Pediatricsmedicine.medical_specialtyDisease onsetbusiness.industryEndocrinology Diabetes and MetabolismEpileptic encephalopathyMucopolysaccharidosisLiver failuremedicine.diseaseBiochemistryEndocrinologyMiglustatGeneticsmedicineSly diseaseSlow disease progressionbusinessMolecular Biologymedicine.drugMolecular Genetics and Metabolism
researchProduct

Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application

2005

To date, various strategies have been developed in order to prevent or to slow down the progression of Alzheimer's disease (AD). Despite the medical need for an effective therapeutic treatment of AD, progress towards this goal is painstakingly slow. Although AD is the most common neurodegenerative disorder and a large amount of primary basic and clinical research has been performed already, it appears very difficult to identify appropriate targets, which would promise fast, effective and safe strategies to combat the disease onset and progression. In this review, we present some of clinically applied treatment options, which may improve AD symptoms for a short period but so far lack the abi…

medicine.medical_specialtyDisease onsetMechanism (biology)business.industryTherapeutic treatmentTreatment optionsCell BiologyDiseasemedicine.diseasePathology and Forensic MedicineSurgeryDegenerative diseaseClinical researchmedicineAlzheimer's diseaseIntensive care medicinebusinessMolecular BiologyInternational Journal of Experimental Pathology
researchProduct